Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer

Mersana Therapeutics, Inc. announced that the FDA has granted orphan drug designation to XMT-2056, the company’s lead Immunosynthen STING-agonist antibody-drug conjugate, for the treatment of gastric cancer.